Phase 3 N=58 Effects of Lavender Oil on Postoperative Pain, Sleep Quality and Mood
Pain, Postoperative
Primary: Effects of Lavender Oil on Postoperative Pain Through Pain Scores — 0.5; 0.9; 3.5; 3.1 score on a scale — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=357 Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
Squamous NSCLC
Primary: PFS(Progression Free Survival) — 5.5; 4.9 months
Phase 3 N=813 A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)
Acne Vulgaris
Primary: Absolute Change in Mean Lesion Counts at Week 12 — -21.0; -16.4; -15.6; -12.4 lesion counts
Phase 3 N=1,484 A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
Psoriasis
Primary: Percentage of Participants With a Static Physician's Global Assessment (sPGA) of (0,1) With at Least a 2-point Improvement From Baseline — 6.3; 76.3; 79.7 percentage of…
Phase 3 N=272 A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus
Type 1 Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 Noninferior to Lantus®) — -0.20; -0.08 Percentage of HbA1c
Phase 3 N=403 Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder
Methamphetamine Use Disorder
Primary: Number of Participants With Treatment Response During Medication Phase at Stage 1 — 10; 18; 284; 91 Participants
Phase 3 N=616 Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
Anemia in Chronic Kidney Disease in Non-dialysis Patients
Primary: Percentage of Participants With a Hb Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy — 89.5; 78.0…
Phase 3 N=627 A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: Objective Response Rate (ORR) at Week 18 — 40.3; 44.6 Percentage of participants
Phase 3 N=934 A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
Prostate Cancer
Primary: Sustained Castration Rate — 96.7; 88.8 percentage of participants — p=< 0.0001
Phase 3 N=628 Preventing Non-communicable Diseases in Guatemala Through Sugary Drink Reduction
Food Preferences
Primary: Volume of SSBs Per Transaction — 116.2; 89.8; 115.3; 103.4 mL of Sugar Sweetened Beverages purchase
Phase 3 N=348 Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women
Infertility
Primary: Number of Oocytes Retrieved — 9.3; 10.5 Oocytes retrieved
Phase 3 N=330 American Trial Using Tranexamic Acid in Thrombocytopenia
Thrombocytopenia
Primary: Bleeding Within 30 Days — 73; 78 Participants
Phase 3 N=74 Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
Influenza
Primary: Safety and Tolerability, as Measured by the Number of Adverse Events. — 17; 9; 1; 5 Participants
Phase 3 N=141 Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III
Chronic Hepatitis C
Primary: Proportion of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 136 Participants
Phase 3 N=64 Omega-3 and Vitamin D Supplements in Childhood T1D
Type 1 Diabetes Mellitus
Primary: Daily Insulin Need (IU/Kg/Day) and Daily Insulin Pre-meal Demand (Pre-meal IU/Kg/Day) at 12 Months — 0.49; 0.63; 0.22; 0.34 IU/Kg/day — p=<0.05